CliffBio
biologic

Flublok

Influenza Vaccine

Loss of exclusivityOctober 2028projected — 12-year biologic exclusivity estimate
CompanyProtein Sciences Corporation →See this company's full patent-cliff portfolio

Drug detail

Brand nameFlublok
Active ingredientInfluenza Vaccine
Strength180UG/.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalOctober 2016
Marketing statusRx

More from Protein Sciences Corporation

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Flublok patent cliff — loss of exclusivity October 2028 | CliffBio